Imatinib - Samyang
Alternative Names: SYO-1126Latest Information Update: 09 Apr 2025
At a glance
- Originator Samyang Biopharmaceuticals Corporation
- Class Amines; Anti-inflammatories; Antineoplastics; Antivirals; Benzamides; Eye disorder therapies; Piperazines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Bcr-Abl tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic myeloid leukaemia
Most Recent Events
- 09 Apr 2025 Discontinued - Phase-I for Chronic myeloid leukaemia (In volunteers) in South Korea (PO), before April 2025
- 16 Jul 2016 No recent reports of development identified for phase-I development in Chronic-myeloid-leukaemia(In volunteers) in South Korea (PO, Tablet)
- 04 Jul 2012 Phase-I clinical trials in Chronic myeloid leukaemia (healthy volunteers) in South Korea (PO)